Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
52 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Charcot-Marie-Tooth Disease Type I A - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Charcot-Marie-Tooth Disease Type I A - Pipeline Review, H2 2016, provides an overview of the Charcot-Marie-Tooth Disease Type I A (Genetic Disorders) pipeline landscape. Charcot-Marie-Tooth disease type 1A (CMT1A) is a type of inherited neurological disorder that affects the peripheral nerves. Symptoms include distal weakness and atrophy, sensory loss, foot deformities, and slow nerve conduction velocity. The disorder is caused by a duplication of the PMP22 gene on Chromosome 17. Symptomatic treatment includes pain medication, physical therapy and surgery. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Charcot-Marie-Tooth Disease Type I A - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Charcot-Marie-Tooth Disease Type I A (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Charcot-Marie-Tooth Disease Type I A (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Charcot-Marie-Tooth Disease Type I A and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively. Charcot-Marie-Tooth Disease Type I A (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Charcot-Marie-Tooth Disease Type I A (Genetic Disorders). - The pipeline guide reviews pipeline therapeutics for Charcot-Marie-Tooth Disease Type I A (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Charcot-Marie-Tooth Disease Type I A (Genetic Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Charcot-Marie-Tooth Disease Type I A (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Charcot-Marie-Tooth Disease Type I A (Genetic Disorders) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Charcot-Marie-Tooth Disease Type I A (Genetic Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Charcot-Marie-Tooth Disease Type I A (Genetic Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Charcot-Marie-Tooth Disease Type I A Overview 6 Therapeutics Development 7 Pipeline Products for Charcot-Marie-Tooth Disease Type I A - Overview 7 Pipeline Products for Charcot-Marie-Tooth Disease Type I A - Comparative Analysis 8 Charcot-Marie-Tooth Disease Type I A - Therapeutics under Development by Companies 9 Charcot-Marie-Tooth Disease Type I A - Therapeutics under Investigation by Universities/Institutes 10 Charcot-Marie-Tooth Disease Type I A - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 Charcot-Marie-Tooth Disease Type I A - Products under Development by Companies 13 Charcot-Marie-Tooth Disease Type I A - Products under Investigation by Universities/Institutes 14 Charcot-Marie-Tooth Disease Type I A - Companies Involved in Therapeutics Development 15 Addex Therapeutics Ltd 15 Affectis Pharmaceuticals AG 16 Genzyme Corp 17 Lead Discovery Center GmbH 18 Pharnext SA 19 Charcot-Marie-Tooth Disease Type I A - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Combination Products 21 Assessment by Target 22 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 27 Drug Profiles 29 (baclofen + naltrexone hydrochloride + sorbitol) - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 ADX-71441 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 AFC-5128 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Small Molecules for Charcot-Marie-Tooth Disease Type I A - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 Small Molecules to Inhibit PMP22 for Charcot-Marie-Tooth Type 1 A - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Stem Cell Therapy for Charcot-Marie-Tooth Disease Type 1A - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 Charcot-Marie-Tooth Disease Type I A - Dormant Projects 40 Charcot-Marie-Tooth Disease Type I A - Product Development Milestones 41 Featured News & Press Releases 41 Dec 20, 2016: Pharnext Completes Patient Enrollment in International Pivotal Phase 3 Trial of PXT3003 for Charcot-Marie-Tooth Disease Type 1A 41 Nov 17, 2016: Pharnext Announces that the Data Safety Monitoring Board Recommends Continuing the Ongoing Phase 3 Trial of PXT3003 for Charcot-Marie-Tooth Disease Type 1A 42 Oct 04, 2016: Pharnext Announces Support of the First Patient-Centered Charcot-Marie-Tooth Summit Organized by the Hereditary Neuropathy Foundation 42 Sep 01, 2016: Pharnext's PXT3003 Featured in Multiple Presentations at the 6th International Charcot-Marie-Tooth and Related Neuropathy Consortium (CMTR) Meeting 43 Apr 25, 2016: Pharnext Announces the Opening of the First U.S. Study Site for its PLEO-CMT International Pivotal Phase 3 Trial in Charcot-Marie-Tooth Disease Type 1A 43 Feb 16, 2016: Pharnext Supports the Fight Against Rare Diseases through Development of Pleotherapy-based Treatments 44 Dec 15, 2015: Pharnext Initiates PLEO-CMT, an International Pivotal Phase 3 Trial, in Charcot-Marie-Tooth disease type 1A 44 Jun 30, 2015: Pharnext's PXT-3003 Featured in Multiple Presentations at 2015 Peripheral Nerve Society Biennial Meeting 45 Dec 17, 2014: Pharnext Announces Pleotherapy Proof of Concept in Charcot-Marie-Tooth Disease Type 1A through Two Peer-Reviewed Publications 46 Oct 21, 2014: Addex And The Charcot-Marie-Tooth Association Enter Collaboration To Advance ADX71441 In Charcot-Marie-Tooth 1A disorder 47 Jun 23, 2014: The EMA and FDA Grant Orphan Drug Designation to Pharnext's PXT-3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A 48 Apr 24, 2013: Addex Receives Approval To Initiate Phase I First-In-man Clinical Study For ADX71441 48 Jan 22, 2013: Addex Receives Broad US Composition Of Matter Patent For ADX71441 49 Jan 07, 2013: Addex Therapeutics Announces Positive Data With ADX71441 In Pre-Clinical Transgenic Model Of Charcot-Marie-Tooth 1A Disease 49 Nov 22, 2011: Pharnext Completes Patient Recruitment For Phase II Study Of PXT3003 In Type 1A Charcot-Marie-Tooth Disease 50 Appendix 51 Methodology 51 Coverage 51 Secondary Research 51 Primary Research 51 Expert Panel Validation 51 Contact Us 51 Disclaimer 5
List of Tables
Number of Products under Development for Charcot-Marie-Tooth Disease Type I A, H2 2016 7 Number of Products under Development for Charcot-Marie-Tooth Disease Type I A - Comparative Analysis, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Number of Products under Investigation by Universities/Institutes, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 11 Comparative Analysis by Early Stage Development, H2 2016 12 Products under Development by Companies, H2 2016 13 Products under Investigation by Universities/Institutes, H2 2016 14 Charcot-Marie-Tooth Disease Type I A - Pipeline by Addex Therapeutics Ltd, H2 2016 15 Charcot-Marie-Tooth Disease Type I A - Pipeline by Affectis Pharmaceuticals AG, H2 2016 16 Charcot-Marie-Tooth Disease Type I A - Pipeline by Genzyme Corp, H2 2016 17 Charcot-Marie-Tooth Disease Type I A - Pipeline by Lead Discovery Center GmbH, H2 2016 18 Charcot-Marie-Tooth Disease Type I A - Pipeline by Pharnext SA, H2 2016 19 Assessment by Monotherapy Products, H2 2016 20 Assessment by Combination Products, H2 2016 21 Number of Products by Stage and Target, H2 2016 23 Number of Products by Stage and Mechanism of Action, H2 2016 25 Number of Products by Stage and Route of Administration, H2 2016 26 Number of Products by Stage and Molecule Type, H2 2016 28 Charcot-Marie-Tooth Disease Type I A - Dormant Projects, H2 2016 40
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
